Vor Biopharma (NASDAQ:VOR) Stock Price Down 3.8% - Time to Sell?

Key Points

• Vor Biopharma's shares declined by 3.8% on Wednesday, trading as low as $1.99 before last seen at $2.00, with a trading volume increase of 7% from average levels.
• Analysts have provided mixed ratings for Vor Biopharma, with HC Wainwright upgrading it to a "strong-buy", while Zacks Research and Wall Street Zen assigned "strong sell" ratings.
• The company reported a loss of $2.18 EPS for the latest quarter, significantly missing analysts' expectations of a loss of $0.57 EPS.

Shares of Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) dropped 3.8% during mid-day trading on Wednesday . The company traded as low as $1.99 and last traded at $2.00. Approximately 4,923,423 shares changed hands during mid-day trading, an increase of 7% from the average daily volume of 4,588,243 shares. The stock had previously closed at $2.08.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Zacks Research upgraded shares of Vor Biopharma to a "strong sell" rating in a research note on Tuesday, August 12th. Finally, HC Wainwright upgraded Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Monday, June 30th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy".

Vor Biopharma Trading Up 5.3%

The stock has a market capitalization of $262.81 million, a PE ratio of -0.15 and a beta of 2.05. The business has a fifty day moving average of $2.10.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($1.61).

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.